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Abstract
Objective: High-sensitivity C-reactive protein (hs-CRP) rises with cardiac injury/ischemia. We evaluated its efficacy in
aiding in the identification of an acute coronary syndrome (ACS) in patients (pts) admitted to the chest pain unit
(CPU) for possible ACS.
Methods: Retrospective study of all patients admitted to the CPU with chest pain who underwent hs-CRP testing
as part of their CPU evaluation from January 2004 to October 2008. Patients were low risk for ACS (compatible
symptoms, nondiagnostic initial ECG, and negative cTnI). ACS was diagnosed by positive functional study, cardiac
catheterization, or cardiac event during 30-day follow-up. Positive hs-CRP was defined based on local laboratory
levels (>1.0 mg/l or >3.0 mg/l), and population-based and prior study values >2.0 mg/l. Chi-square analysis was
performed, and odds ratios (OR) are presented. Multivariate analysis was done to determine whether hs-CRP was
independently associated with the diagnosis of ACS. Cardiac risk factors, demographics, and diagnosis of ACS were
included in the model. Medians with IQR are presented for continuous data. Ninety-five percent confidence
intervals are presented where applicable.
Results: A total of 958 patients had hs-CRP testing as part of their CPEU evaluation. Excluded from the analysis
were 39 patients lost to follow-up. The final cohort comprised 478 (52%) women and 441 (48%) men with a
median age of 56 (IQR 48-64). ACS was diagnosed in 128 (13.4%). The median cohort hs-CRP value was 2.2 mg/l
(IQR 0.7, 5.8) and 2.3 mg/l (IQR 0.6, 5.9) in those with and without ACS, respectively. In the multivariate analysis
hs-CRP was not independently associated with the diagnosis of ACS (0.99; 95% CI 0.98 - 1.01).
Conclusion: In large patient cohort managed in a single-center CPU, measurement of hs-CRP did not enhance the
diagnostic accuracy for ACS. Routine hs-CRP as a diagnostic tool should not be recommended in the CPU setting.
Introduction
The management of patients presenting to the emer-
gency department (ED) with chest pain is a continuing
challenge. Of primary concern is recognition or exclu-
sion of an acute coronary syndrome (ACS), which is
initiated with risk stratification that encompasses a pro-
tocol-driven approach that begins with the patient’sh i s -
tory, physical examination, and electrocardiogram,
(ECG) [1]. This method provides early evidence of the
presence or absence of myocardial ischemia/injury. In
those patients with negative findings, which indicate low
or moderate clinical risk depending on individual clini-
cal characteristics, normal cardiac injury markers further
reduce the probability of ACS and subsequent adverse
clinical events. The injury markers currently utilized are
the cardiac troponins, the myocardial band (MB) of
creatinine kinase, and myoglobin. The findings of nor-
mal confirmatory evaluation such as a treadmill stress
test in addition to this negative initial evaluation identi-
fies a group of patients that can be safely discharged
from the ED with early follow-up [1].
Numerous biomarkers have been investigated for the
rule in the pathophysiology of ACS, including markers
of inflammation [2,3]. Acute inflammation is an impor-
tant factor in ACS through its role in coronary plaque
disruption and other aspects of the pathophysiology of
this syndrome. The association of inflammation with
ACS is reflected by an increase in multiple inflammatory
markers that can be detected as acute phase reactants.
High-sensitivity C-reactive protein (hs-CRP) is a
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provided the original work is properly cited.non-specific marker of inflammation that has been
shown to have prognostic significance in patients with
coronary artery disease [4,5]. This property has led to
the evaluation of hs-CRP as a diagnostic tool in patients
presenting to the ED with chest pain, and the diagnostic
utility of hs-CRP in this setting has been variable
depending on the patient populations studied [6-9]. In
this investigation we evaluated the diagnostic accuracy
of hs-CRP in low risk patients evaluated for ACS in our
chest pain unit (CPU) in order to determine whether
this marker can aid in the discrimination of those with
and without ACS.
Methods
This is a secondary analysis of prospective data from a
single urban tertiary medical center CPU from 1 April
2004 to 31 October 2008. The study was approved by
our institutional review board.
Patient population
Inclusion criteria
All patients with a chief complaint of chest pain or an
anginal equivalent referred to our CPU were eligible for
this study. Our CPU accepts patients who have been
evaluated by the ED physician for suspicion of ACS, but
are considered low risk based on a normal cardiac injury
marker profile and a normal, non-diagnostic, or
abnormal but unchanged ECG [10]. Depending on the
individual patient risk, patients are further risk stratified
by a variety of methods that include obtaining serial
ECGs and cardiac injury markers, and performance of
confirmatory testing, such as stress electrocardiography,
myocardial perfusion imaging, stress angiography, and
coronary angiography. Serum hs-CRP was ordered in
these patients at the discretion of the CPU physician.
Only those patients who underwent hs-CRP testing
were included in this analysis.
High-sensitivity C-reactive protein
We utilized hs-CRP by Beckman SYNCHRON LX. The
manufacturer’s threshold for an abnormal value inter-
mediate for cardiovascular events was 1.0 mg/l to 3.0
mg/l and high risk >3.0 mg/l.
Outcome measure
The outcome measure of ACS was defined by ischemia
on ECG cardiac marker elevation, or an abnormal con-
firmatory test indicating the presence of coronary artery
disease (CAD). Lack of ACS was determined by negative
diagnostic testing or absence of a cardiac event (death,
myocardial infarction, or revascularization) during the
30-day follow-up period. Patients lost to follow-up and/
or who did not undergo a diagnostic test were excluded
from the analysis.
Statistical analysis
Hs-CRP threshold
We evaluated the thresholds for intermediate risk and
high risk based on manufacturer recommendations. The
dichotomous threshold for hs-CRP was created using
the ROC curve. We also evaluated the hs-CRP threshold
≥2.0 mg/l based on a recent large clinical trial [11].
Continuous data were assessed for normality, and
median interquartile ranges are presented. Measures of
association were performed (odds ratio) and diagnostic
test characteristics determined. Sensitivity, specificity,
and likelihood ratios were calculated and 95%
confidence intervals (CI) presented for local laboratory
hs-CRP thresholds as defined above, population thresh-
old defined by the ROC curve, and the value used in
clinical trials.
Logistic regression was performed to determine if
hs-CRP was independently associated with the diagnosis
of ACS. Covariates associated with the diagnosis of ACS
were entered into the regression analysis (age, gender,
cocaine or methamphetamine use, past medical history
of diabetes, hypertension, hypercholesterolemia, family
history of myocardial infarction, tobacco use, prior
history of CAD, and a normal electrocardiogram).
Hs-CRP was evaluated as a continuous variable
(Table 1). All analyses were performed on Stata 9.0,
(College Station, TX).
Results
A total of 958/3,173(30.2%) patients had hs-CRP testing
as part of their CPU evaluation. Of these 958 patients,
40 (4.1%) were lost to follow-up and therefore excluded
from the study. The final cohort comprised 918 patients,
including 478 (52%) women and 441 (48%) men with a
median age of 56 years (IQR 48-64 years). Demographic
data are presented in Table 2. Confirmatory testing
Table 1 Regression analysis for the association of hs-CRP
with the diagnosis of acute coronary syndrome
Variable Adjusted OR (95% CI)
Age (year) 1.03 (1.01-1.05)
Male gender 1.71 (1.12-2.61)
Prior CAD 2.80 (1.77-4.41)
Family history of CAD 1.33 (0.86-2.08)
Hypertension 1.34 (0.78-2.33)
Cholesterol 1.68 (1.03-2.78)
Diabetes mellitus 0.97 (0.62-1.51)
Tobacco 1.43 (0.92-2.24)
Cocaine 0.59 (0.16-2.15)
Amphetamine 2.2 (0.79-6.32)
Normal ECG 0.71 (0.47-1.07)
hs-CRP mg/l 0.99 (0.98-1.01)
CAD, coronary artery disease; ECG, electrocardiogram; hs-CRP, high sensitivity
C reactive protein
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diography (n = 327), myocardial perfusion scintigraphy
(n = 251 stress, n = 59 rest), stress echocardiography
(n = 83), and coronary angiography (n = 178). The final
outcome of ACS was diagnosed in 128 (13.4%).
The median cohort hs-CRP value was 2.2 mg/l (IQR
0.7, 5.8) and 2.3 mg/l (IQR 0.6, 5.9) in those with and
without ACS, respectively (Figure 1). Based on the
population-based ROC curve, no threshold for hs-CRP
to predict the diagnosis of ACS could be defined
(Figure 2). Using a threshold defined in prior clinical
trials, an elevated hs-CRP had a sensitivity, specificity,
positive likelihood ratio, and negative likelihood ratio for
ACS of 53.1%, 50.3%, 1.05, and 0.99, respectively. In
addition, measures of diagnostic accuracy are presented
for all studied thresholds in Table 3.
The 40 patients who were excluded from the study
b e c a u s et h e yw e r el o s tt of o l l o w - u pd i f f e r e ds l i g h t l y
from the overall cohort. These patients had a lower pre-
valence of both hypertension and elevated cholesterol
than the study cohort.
Discussion
In this study of low-moderate risk patients admitted to
our CPU who underwent hs-CRP testing, we found little
diagnostic utility for detection of ACS as defined by a
positive confirmatory study or subsequent adverse
cardiac event during a limited post-discharge interval.
This study adds to the limited information on hs-CRP
as a diagnostic tool in patients presenting to the ED
with chest pain.
The initial evaluation of CRP in the setting of acute
evaluation, did not utilize a high-sensitivity assay. Prior
studies evaluating the use of CRP in the acute setting
vary with the risk of disease, length of follow-up, and
type of CRP testing utilized. Magadle et al. measured
Table 2 Patient demographic data and factors associated
withdiagnosis of ACS
Variable ACS, No ACS,
N = 128 (%) N = 790 (%)
Age (years) (mean; SD) (56.2; 12.0) (61.4; 12.2)
Male gender 78 (60.9) 362 (45.8)
Prior disease 60 (46.8) 119 (15.0)
Family history of CAD 42 (32.8) 232 (29.3)
Hypertension 106 (82.8) 525 (66.4)
Cholesterol 98 (76.5) 412 (52.1)
Diabetes mellitus 43 (33.6) 228 (28.8)
Tobacco 53 (41.4) 268 (33.9)
Cocaine 4 (3.1) 30 (3.8)
Amphetamine 7 (5.4) 21 (2.6)
Normal ECG 52 (40.6) 456 (57.7)
ACS, acute coronary syndrome; SD, standard deviation; CAD, coronary artery
disease; ECG, electrocardiogram
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Figure 1 hs-CRP values in presence of acute coronary syndrome.
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chest pain who were followed for 1 year and in whom
the outcome measure was occurrence of coronary
events. Based on a diagnostic threshold for CRP of 25
mg/l, sensitivity for the diagnosis of ACS was 93%,
specificity 65%, and negative predictive value 96% [8].
This study excluded 100 patients because of medical
conditions other than CAD that may elevate CRP.
Mitchell et al. evaluated a convenience sample of 414
patients admitted to a CPU in whom the prevalence of
ACS was 1.7%. Utilizing a multi-marker panel, they
found that the negative likelihood ratio for CRP was
0.79 (95% CI 0.4-1.01) [6]. Liyan et al. evaluated 113
patients presenting to the ED within 12 h of chest pain
onset. Ninety patients had a final diagnosis of ACS
[11]. Using a population-based threshold for CRP of
≥3.16, the sensitivity for diagnosis of ACS was 70%
and specificity 74% [12]. Despite the differences in the
study populations, the relatively consistent negative
results of the foregoing studies suggest the diagnostic
accuracy of CRP adds little to the assessment of these
patients.
Our study evaluated the use of a contemporary
hs-CRP at a single point in time. Lozona et al. evaluated
a subgroup of 191 ED patients with an inconclusive
cause of chest pain and determined the diagnostic value
of a change in two measurements of hs-CRP. In the
cohort of 191 patients, 38 had a diagnosis of ACS. All
patients completed a CPU protocol with functional test-
ing or coronary angiography. There was no difference in
the initial hs-CRP values between the groups of patients
with and without CAD [7]. However, in those patients
with an increase in hs-CRP from presentation to 24 h
later, the sensitivity, specificity, likelihood ratio (LR)+,
and LR- for the diagnosis of ACS were 95 (95% CI 81,
98), 40% (95% CI, 32, 47), 1.57 (95% CI, 1.33, 1.83), and
0.13 (95% CI 0.04, 0.44), respectively [7]. This study sug-
gests that changes in hs-CRP may be more reflective of
an acute coronary process, although the specificity was
unsatisfactory.
Limitations
This study is a retrospective analysis of existing clinical
data. Our CPU protocol does not mandate that all
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Figure 2 ROC curve for the diagnostic accuracy of hs-CRP.
Table 3 Measures of diagnostic accuracy for the diagnosis of acute coronary syndrome
Hs-CRP thresholds Sensitivity Specificity Likelihood ratio positive Likelihood ratio negative
≥1.0 mg/l 68% (59.1%-75.9%) 32% (28.9%-35.3%) 1.00 (0.88-1.14) 0.99 (0.76-1.31)
>3.0 mg/l 43.8% (35.2%-52.8%) 58.5% (55.0%-61.9%) 1.05 (0.85-1.3) 0.96 (0.81-1.13)
≥2.0 mg/l 53.1% (49.6%-67.7%) 50.3% (46.8%-53.9%) 1.05 (0.76-1.45) 0.99 (0.94-1.04)
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fore, not all patients had diagnostic tests for CAD per-
formed, and this may have underestimated the true
incidence of ACS in our patient population. Patients
admitted to our CPU have risk factors for coronary
artery disease, such as diabetes, and therefore this popu-
lation may have increased CRP values when compared
to a patient population that lacks these risk factors for
cardiac disease. Although hs-CRP is on our standard
order form for the CPU, not all patients underwent hs-
CRP testing, which could have resulted in selection bias.
Physicians were not blinded to the results of the hs-CRP
value, and it is possible that medications with potential
anti-inflammatory actions, such as statins, may have
been initiated as a result of a high value, which could
have altered the risk of subsequent cardiac events within
the 30-day follow-up period. In addition, we evaluated
hs-CRP only in the context of its diagnostic value for
ACS. It is possible that the true value of hs-CRP may be
related to mortality or identification of an alternative
diagnosis as prior studies have shown that hs-CRP has
prognostic value [11].
Conclusion
In our large patient cohort, managed at a single-center
CPU, measurement of hs-CRP did not enhance the diag-
nostic accuracy for detecting ACS. Based on our study,
we do not recommend routine measurement of hs-CRP
as a diagnostic tool in this patient population.
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